IND-enabling biopharmaceutical developer of novel combination and immunotherapies that synergize complementary biological pathways to treat cancer. Pipelines use local (AIRISE) and systemic (ARAC) approaches to bridge innate and adaptive immunity, elicit robust CD8+ T-cell responses, and exploit the patient's tumor in situ as the antigen source.